Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Travere Therapeutics Inc’s stock clocked out at $29.81, up 0.13% from its previous closing price of $29.77. In other words, the price has increased by $0.13 from its previous closing price. On the day, 1.84 million shares were traded. TVTX stock price reached its highest trading level at $30.97 during the session, while it also had its lowest trading level at $29.37.
Ratios:
To gain a deeper understanding of TVTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 12.20 whereas as Long-Term Debt/Eq ratio is at 9.93.
On June 11, 2025, Citigroup reiterated its Buy rating and also upped its target price recommendation from $35 to $32.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 28 ’25 when Dube Eric M bought 92,872 shares for $30.38 per share.
Heerma Peter bought 2,662 shares of TVTX for $79,860 on Oct 28 ’25. On Sep 22 ’25, another insider, REED ELIZABETH E, who serves as the Chief Legal Officer and GC of the company, sold 10,000 shares for $25.00 each. As a result, the insider received 250,000 and left with 89,878 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 2657223680 and an Enterprise Value of 2737259776. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.96 while its Price-to-Book (P/B) ratio in mrq is 81.11. Its current Enterprise Value per Revenue stands at 8.199 whereas that against EBITDA is -22.708.
Stock Price History:
The Beta on a monthly basis for TVTX is 0.90, which has changed by 0.67671084 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, TVTX has reached a high of $29.81, while it has fallen to a 52-week low of $12.91. The 50-Day Moving Average of the stock is 25.90%, while the 200-Day Moving Average is calculated to be 53.99%.
Shares Statistics:
It appears that TVTX traded 2.07M shares on average per day over the past three months and 1769800 shares per day over the past ten days. A total of 89.10M shares are outstanding, with a floating share count of 86.74M. Insiders hold about 2.69% of the company’s shares, while institutions hold 119.25% stake in the company. Shares short for TVTX as of 1760486400 were 11840340 with a Short Ratio of 5.72, compared to 1757894400 on 12319282. Therefore, it implies a Short% of Shares Outstanding of 11840340 and a Short% of Float of 13.38.
Earnings Estimates
The dynamic stock of Travere Therapeutics Inc (TVTX) is currently attracting attention from 8.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.01, with high estimates of $0.29 and low estimates of -$0.17.
Analysts are recommending an EPS of between $0.08 and -$1.04 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is $1.13, with 6.0 analysts recommending between $1.86 and $0.05.
Revenue Estimates
In. The current quarter, 14 analysts expect revenue to total $106.09M. It ranges from a high estimate of $116.01M to a low estimate of $98.95M. As of. The current estimate, Travere Therapeutics Inc’s year-ago sales were $62.9MFor the next quarter, 14 analysts are estimating revenue of $117.54M. There is a high estimate of $151.1M for the next quarter, whereas the lowest estimate is $102.03M.
A total of 15 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $458.5M, while the lowest revenue estimate was $397.16M, resulting in an average revenue estimate of $419.51M. In the same quarter a year ago, actual revenue was $233.18MBased on 14 analysts’ estimates, the company’s revenue will be $590.46M in the next fiscal year. The high estimate is $795.9M and the low estimate is $468.83M.
